Latest Articles
- Short-term prognosis after a TIA: A simple score predicts risk
This article discusses the defining features of transient ischemic attacks (TIAs), and their immediate evaluation and management.
- Ulcerative colitis: Responding to the challenges
Aminosalicylates are the first-line therapy for patients with mild to moderate active ulcerative colitis. Infliximab is now approved for moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy.
- Interpreting the Courage Trial
We found that as an initial management strategy in patients with stable coronary artery disease, percutaneous coronary intervention did not reduce the incidence of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy.